Inquiry Basket
Loading ......
Filter By Product Search for
CDKN1B
CDKN1B Full Name
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
CDKN1B Introduction
CDKN1B (cyclin-dependent kinase inhibitor 1B), encoding the p27^Kip1 protein, is a central gatekeeper of cell-cycle progression that restrains cyclin–CDK activity and controls the critical transition from G1 to S phase. For researchers addressing uncontrolled proliferation in cancer and hyperplastic diseases, CDKN1B represents a pivotal checkpoint node where external growth signals are either translated into proliferation or effectively blocked. The p27^Kip1 protein is an intrinsically disordered regulator with high structural flexibility, enabling it to interact with multiple signaling partners. Its activity is tightly controlled by phosphorylation, ubiquitin-mediated degradation, and subcellular localization, which collectively determine whether a cell remains in quiescence or re-enters the cell cycle. This regulatory plasticity makes CDKN1B a key integrator of proliferative signaling and a fundamental determinant of cellular growth restraint.
Beyond classical cell-cycle control, CDKN1B plays broader roles in immune regulation, tissue homeostasis, and regeneration biology. In immune systems, impaired autophagy can disrupt CDKN1B degradation, leading to its accumulation and subsequent suppression of CD8+ cytotoxic T-cell proliferation, thereby weakening antitumor immune responses and contributing to immune dysfunction. In regenerative contexts, CDKN1B acts as a molecular barrier that maintains terminal differentiation states in tissues such as the inner ear and retina. Even when pro-regenerative signaling pathways are activated, sustained CDKN1B expression can prevent differentiated cells from re-entering the cell cycle, effectively limiting tissue regeneration capacity. These findings highlight CDKN1B as a context-dependent regulator that balances immune competence, cellular quiescence, and regenerative potential.
Clinically, CDKN1B alterations are increasingly recognized as important drivers of tumor susceptibility and disease heterogeneity across multiple cancer types. Mutations in CDKN1B are associated with endocrine tumor syndromes such as MEN4, as well as breast cancer, prostate cancer, and neuroendocrine tumors, where they disrupt normal cell-cycle inhibition and enhance proliferative signaling. In pancreatic neuroendocrine tumors, CDKN1B mutations contribute to a complex molecular landscape alongside other key tumor suppressors, influencing metabolic stress responses, mitochondrial dysfunction, and overall tumor heterogeneity. These insights position CDKN1B as both a critical tumor suppressor gene and a clinically relevant biomarker, with growing importance in precision oncology, where its status may inform prognosis, tumor classification, and potential therapeutic targeting strategies.
Alternate Names for CDKN1B
CDKN1B; cyclin-dependent kinase inhibitor 1B (p27, Kip1); cyclin-dependent kinase inhibitor 1B; KIP1; P27KIP1; AA408329; AI843786; Cdki1b; CDKN 1B; CDKN 4
Loading ......
